ArticleJournal of advanced pharmaceutical technology & research
Preparation and evaluation of topical span 60-based oleogel of voriconazole.
Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and fabrication of apricot kernel oil-based oleogels for enhanced ocular delivery of lifitegrast in dry eye management.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Erratum: Preparation and evaluation of topical span 60-based oleogel of voriconazole.Journal of advanced pharmaceutical technology & researchArticle
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Voriconazole (VOR) is a triazole antifungal agent; it blocks the synthesis of ergosterol, available in the market orally and intravenously, but, not without various side effects. The aim of this study is development and characterization of VOR oleogel for the topical treatment of skin fungal infection to avoid the drug's systemic side effects that are associated with oral and IV routes. The gelator Span 60 (S) was added at different concentrations to different oils (oleic OO, grapeseed GO, and sesame oil SO) to obtain the minimum gelation concentration, the prepared formulas were subjected to various evaluation tests, and the optimum formula was checked for antifungal effect, and subjected to viscosity, and texture analysis. The optimized formula, Span60 with SO 14SSO, showed 100% drug release, good antifungal activity, and acceptable transition temperature. The study of viscosity demonstrated the pseudo-plastic shear thinning behavior. A Fourier-transform infrared study showed that the drug and excipients did not significantly interact. 14SSO might be a promising topical treatment option for skin fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.